Search | Clinical Trials Finder

Conditions: Bioequivalence
Interventions: Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC], Canagliflozin, Metformin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Sin Health, Skin Hydration, Skin Wrinkles, Skin Porphyrins, Facial Skin Red Spots, Facial Skin Red Vasculature
Interventions: äKwä skincare system products, competitor products (control); Other
Lead sponsor: 4Life Research, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Sandy City, Utah

Conditions: Blepharoptosis
Interventions: RVL-1201, Vehicle ophthalmic solution; Drug · Other
Lead sponsor: RVL Pharmaceuticals, Inc.; Industry
Eligibility: 9 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 36
States / cities: Phoenix, Arizona • Garden Grove, California • Mission Hills, California + 30 more

Conditions: Healthy Volunteer
Interventions: Part 1: SAD RO7033877, Part 1: SAD placebo, Part 2: Treatment A, RO7033877, Part 2: Treatment B, RO7033877, Part 2: Treatment C, moxifloxacin, Part 2: Treatment D, RO7033877 and moxifloxacin placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Rosacea, Erythema
Interventions: Oxymetazoline; Drug
Lead sponsor: Padagis LLC; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Healthy
Interventions: UT-15C, ethanol; Drug · Other
Lead sponsor: United Therapeutics; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Anaemia
Interventions: GSK1278863 75 mg, GSK1278863 500 mg, Moxifloxacin 400 mg, Placebo matching GSK1278863, Placebo matching Moxifloxacin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Parkinson's Disease, Dyskinesia
Interventions: Eltoprazine HCl, Placebo; Drug
Lead sponsor: Amarantus BioScience Holdings, Inc.; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Hypotension, Arterial Stiffness
Interventions: SphygmoCor system; Device
Lead sponsor: University of Iowa; Other
Eligibility: 50 Years to 85 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Obstetric Labour, Premature
Interventions: Retosiban 100 mg, Retosiban 800 mg, Placebo, Moxifloxacin 400 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Mucositis, Stomatitis
Interventions: phenylephrine solution; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: verapamil; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hypoxia
Interventions: Vasoconstrictor Agents, Head/neck repositioning, Increase ETCO2, IV fluid bolus, Additional anesthesia, RBC transfusion, Increase FiO2; Drug · Other · Biological
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 65 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Knee-extensor exercise test, Exercise test with restricting/releasing blood flow, Exercise test with variable oxygen concentration and MRI, Exercise test with oral antioxidant or placebo cocktail; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy
Interventions: Silenor 6 mg, zolpidem 10 mg, Placebo; Drug
Lead sponsor: Currax Pharmaceuticals; Industry
Eligibility: 21 Years to 50 Years · Male only
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Novi, Michigan

Conditions: Spinal Cord Injuries, Autonomic Imbalance, Autonomic Dysreflexia, Orthostatic Hypotension
Interventions: Tests of sympathetic inhibition, Tests of sympathetic activation, Testing of autonomic dysreflexia; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 50 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Hypertension, Hypertension, Essential
Interventions: Angiotensin (1-7), Trimethaphan, Phenylephrine; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Intraoperative Hypotension
Interventions: Phenylephrine, Saline Control; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Healthy Subjects
Interventions: PF-06751979 single ascending dose, Placebo single dose, PF-06751979 multiple ascending dose, Placebo multiple dose, PF-06751979 multiple dose; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Glendale, California

Conditions: Heart Failure
Interventions: phenylephrine; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Blindness
Interventions: initial system, modified system; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Decatur, Georgia • Baltimore, Maryland

Conditions: Hypotension
Interventions: Colloid administration, Crystalloid administration, phenylephrine infusion; Other · Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Uterine Atony, Hypotension
Interventions: Oxytocin Infusion, Oxytocin Bolus; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

Clinical Study to Evaluate the Impact of aKwa Skincare System on Skin Health

Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis

A Two-part, Single-dose, Randomized Study to Evaluate the Safety of Supra-therapeutic Doses of RO7033877 and to Investigate the Effect of RO7033877 on the QTc Interval

An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea

Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers

Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers

A Study of Efficacy and Safety of Eltoprazine HCl for Treating Levodopa-induced Dyskinesia in Parkinson's Disease Patients

Arterial Stiffness and General Anesthesia Induced Hypotension in Patients on Angiotensin-converting Enzyme Inhibitors

This Study Will Investigate the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, With Moxifloxacin as a Positive Control in Healthy Volunteers.

Safety of Phenylephrine for Oral Mucositis Prevention

Bioequivalence Study Of Verapamil

Cerebral Oximetry in Single Lung Ventilation Thoracic Surgery

Exercise in Health and Chronic Obstructive Pulmonary Disease

Assess the Effect of Zolpidem, Silenor & Placebo on Arousability, Ataxia/Balance & Cognition in Healthy Volunteers

Deciphering Preserved Autonomic Function After Spinal Cord Injury

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension

Phenylephrine and Pulse Pressure Variability

First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979

The Development of Tolerance to α1-Adrenoceptor Blockade With Chronic Carvedilol Treatment

Computer Vision System for the Blind Veteran

Spinal Anesthesia Induced Hypotension During Cesarean Section

Oxytocin And Uterotonic Agent Use For Cesarean Delivery